Full-Time
Clinical-stage gene therapy company developing AAVs
No salary listed
Durham, NC, USA
In Person
AskBio focuses on developing adeno-associated virus (AAV) gene therapies for genetic and complex disorders. Therapies use AAV vectors to deliver therapeutic DNA into patients’ cells, advancing from research and preclinical work through clinical trials toward commercialization. Its differentiation comes from a clinical-stage portfolio, in-house R&D, and partnerships that emphasize collaboration and shared development. Its goal is to bring gene therapies to patients with unmet medical needs by validating therapies clinically and pursuing strategic collaborations for commercialization.
Company Size
501-1,000
Company Stage
Acquired
Total Funding
$4.2B
Headquarters
Durham, North Carolina
Founded
2001
Help us improve and share your feedback! Did you find this helpful?
People at AskBio who can refer or advise you
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Sabbatical Leave
Hybrid Work Options
Stock Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Performance Bonus
Profit Sharing
Employee Stock Purchase Plan
Relocation Assistance
Employee Referral Bonus
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Pet Insurance
Bereavement Leave
Professional Development Budget
Conference Attendance Budget
Training Programs
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Wellness Program
Mental Health Support
Gym Membership
Commuter Benefits
Meal Benefits
Phone/Internet Stipend
Home Office Stipend
Legal Services
Employee Discounts
Company Social Events
a-Klotho cell and gene therapy potential. 25 March 2026 Avaí Bio recently announced that it has initiated manufacturing of a master cell bank of genetically modified cells that overexpress the α-Klotho protein, working alongside joint venture partner Austrianova through their shared entity, Klothonova. A Master Cell Bank isn't a research milestone. It's a manufacturing milestone. It's the GMP-compliant, fully characterized starting material from which all working cell banks and final therapeutic products will be produced. It's the moment a cell therapy programme transitions from "we think this could work" to "we're building the production infrastructure to deliver it." There is a key 'master' protein in your body called α-Klotho. The scientific community has been quietly obsessed with it since a Japanese researcher named Makoto Kuro-O discovered in 1997 that mice without the Klotho gene aged rapidly and died young - and mice with extra Klotho lived 30% longer. Since then, the research has only gotten more compelling. Peer-reviewed studies have linked higher Klotho levels to reduced risk of Alzheimer's, certain cancers, cardiovascular disease, and kidney failure. Mayo Clinic research has connected declining Klotho to arterial stiffness and vascular calcification. And here's the part that makes this personal: natural α-Klotho levels drop by approximately 50% after age 40. The protein that protects your brain, your heart, and your kidneys starts disappearing right when you need it most. The question the biotech industry is now racing to answer is simple: can you put it back? The global cell therapy market has surpassed $8.2 billion in 2026. The broader cell and gene therapy sector is forecast to surge from $10.4 billion to more than $45 billion by 2035. And at the intersection of regenerative medicine and longevity science, a small biotechnology company just hit a manufacturing milestone that turns the Klotho thesis from laboratory theory into production reality. The Cell-in-a-Box(R) technology is the delivery mechanism that makes the whole approach viable. When you transplant therapeutic cells into a patient, the immune system typically destroys them within days. Austrianova's encapsulation technology protects the cells inside a porous capsule, allowing the cells to continuously produce and secrete the target protein - in this case, α-Klotho - while protecting the cells from immune rejection. It's backed by over 50 peer-reviewed publications and decades of development. Avaí Bio's dual-programme approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, each leveraging the same Cell-in-a-Box(R) encapsulation technology. The addressable markets are enormous: Alzheimer's disease alone is projected to reach $32.8 billion by 2033, cardiovascular disease remains the leading cause of death globally, and kidney disease affects 850 million people worldwide.
Through AskBio, a wholly owned subsidiary of Bayer, it is developing a gene therapy as a potential new approach for treating congestive heart failure.
Brain Neurotherapy Bio, Inc (BNB) is pleased to announce its recent merger with Asklepios BioPharmaceutical, Inc (AskBio), a Bayer company.
Belief BioMed to collaborate with AskBio to explore the potential of new gene therapies.
As it advances its pipeline of gene therapies, AskBio is planning to expand in the Triangle, essentially doubling its local footprint by acquiring space in Morrisville on Airport Road.